|
| |
XIAP
Gene Information from Publications |
| Publication Link |
Summary of findings |
| 18068526 |
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) |
| 18068526 |
These results suggest that XIAP polymorphisms do not significantly affect susceptibility to lung cancer in Koreans. |
| 18251743 |
XIAP elevation may be correlated with increasing melanoma thickness and tumor progression. |
| 18068114 |
These results indicate that Nulp1 plays a role in cell death control and may influence tumor growth. |
| 17534699 |
XIAP and Survivin are not involved in the cytoprotective effect of HGF against antineoplastic agents. |
| 18022123 |
findings suggest that the potent apoptotic inhibitor XIAP may be a biomarker in head and neck SCCs. |
| 17967870 |
identify apoptosis-inducing factor as a new XIAP binding partner and indicate a role for XIAP in regulating cellular reactive oxygen species |
| 17947468 |
XIAP is expressed at higher levels in prostate cancers compared with matched normal tissues and may have a role in reducing risk of tumor recurrence |
| 17724022 |
XIAP homotrimerizes via its C-terminal Ring domain, making its inhibitory activity toward caspase-3 more susceptible to Smac. |
| 17698078 |
Data report the crystal structure of XIAP and suggest that dimerization may be important for its action in TGF-beta and BMP signaling and the action of cIAP1 and cIAP2 in TNF receptor signaling. | →View more information from publications. |
Recent Publications on XIAP: |  |
Inhibitory Effect of Baicalein on IL-6-Mediated Signaling Cascades in Human Myeloma Cells.
Abstract Interleukin 6 (IL-6) is an important growth factor for myeloma... | 3rd November, 2009
| Department of Hematology, Zhongnan Hospital of Wuhan University, 169
| Eur J Haematol. 2009 Oct 28.
DOI Direct Link |
The 423Q polymorphism of the X-linked inhibitor of apoptosis gene influences monocyte function and is associated with periodic fever.
OBJECTIVE: Hereditary periodic fever syndromes (HPFs) develop as a result... | 31st October, 2009
| Interdisciplinary Research Centre of Autoimmune Diseases, and University
| Arthritis Rheum. 2009 Oct 29;60(11):3476-3484.
DOI Direct Link |
A role for X-linked inhibitor of apoptosis protein upstream of mitochondrial permeabilization.
Apoptosis is controlled by a signalling equilibrium between pro-survival... | 31st October, 2009
| University of Manchester, United Kingdom.
| J Biol Chem. 2009 Oct 29.
DOI Direct Link |
XIAP regulates cell death induction by pro-apoptotic receptor agonists.
Pro-apoptotic receptor agonists cause cellular demise through the... | 27th October, 2009
| Genentech, Inc., United States.
| J Biol Chem. 2009 Oct 23.
DOI Direct Link |
STX140 and STX641 cause apoptosis via the intrinsic mitochondrial pathway and down-regulate survivin and XIAP expression in ovarian and prostate cancer cells.
Many anticancer drugs target microtubules and induce apoptosis. However,... | 23rd October, 2009
| Oncology Drug Discovery and Women's Health Group, Faculty of Medicine,
| Anticancer Res. 2009 Oct;29(10):3751-7.
|
→View more research publications. |
Press Releases on XIAP:
|
 |
| Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) |
19th November, 2009 |
AEGERA THERAPEUTICS INC. |
MONTREAL, Nov. 19 /PRNewswire/ - Aegera Therapeutics Inc. announced today the dosing of the first patient in a randomized Phase 2B study of AEG35156, a targeted antisense therapeutic in mid-stage
|
| Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain |
6th May, 2009 |
AEGERA THERAPEUTICS INC. |
MONTREAL, May 6 /PRNewswire/ - Aegera Therapeutics is pleased to announce the initiation of a Phase 2a, proof-of-concept, clinical trial for AEG33773, a novel, orally bio-available small molecule
|
| Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models |
21st April, 2009 |
Ascenta Therapeutics, Inc. |
- Data on novel pro-apoptotic agent presented at the 100th Annual Meeting of the American Association for Cancer Research -
- University
|
| Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer |
8th January, 2009 |
AEGERA THERAPEUTICS INC. |
MONTREAL, Jan. 8 /PRNewswire/ - Aegera Therapeutics Inc. announced today the dosing of the first patient in a randomized Phase 2 study of AEG35156, their targeted antisense therapeutic in mid-stage
|
| Aegera Initiates a Fifth Phase 1 and 2 Clinical Trial for AEG35156 |
31st July, 2008 |
Aegera Therapeutics Inc. |
MONTREAL, July 31 /PRNewswire/ -- Aegera Therapeutics Inc. is pleased to
announce the dosing of the first patient in a fifth phase 1 and 2 clinical
oncology study of AEG35156, a second
|
XIAP results (if any) from reagent suppliers | 
|
Search Bioportfolio and other Life Science Sites for XIAP,
or search for XIAP on BioPortfolio's antibody search engine.
This page has been viewed 556 times
Recent Search Terms used to find this page: IAP(XIAP) apoptotic biomarker in clinical trials | TGF-betaand XIAP | alk1 xiap | XIAP patents 2009 | GDF5 and BMP2 inhibit apoptosis via activation of BMPR2 and subsequent stabilization of XIAP | Biomarker and XIAP | AT406 IAP | xiap 2009 | apoptosis inhibitors in clinical trial | .
Resources from the NCBI used on this page, NCBI's standard disclaimer applies.
|
